Initiate measured overweight in TXN at $281 with 35-40% initial deployment and disciplined scale-in plan
The Neutral analyst correctly synthesizes both the Aggressive (fundamental inflection is real, HOLD is non-decision) and Conservative (50% upfront at top-of-range P/E into binary catalyst with hostile macro leaves no margin for error) positions. Engage with the trend at 35-40% initial sizing, preserve dry powder for the $260-275 scale-in zone, add time-stop discipline per the 9/29 reflection, and define explicit Q3 triggers. This is constructive accumulation on weakness—not a chase at the highs and not a full defensive retreat—from a franchise with elite ROE, expanding margins (three consecutive quarters of GM expansion: 55.9% → 58.0% → 61.4%), and inflecting FCF (Q2 2026 FCF of $2.19B). The 12-18 month structural thesis (CapEx normalization, 300mm cost moat, 23-year dividend streak) is intact; the 4-6 week tactical execution is calibrated to the binary Q3 catalyst that will determine whether the market finally rewards it.
| Position | Action |
|---|---|
| Current market price ($281) | Deploy 35-40% of target allocation as initial tranche |
| $275 on macro stabilization or volume >6M | Add 20-25% of target allocation (Tranche 2) |
| $267 on confirmed close below 10 EMA with RSI reset toward 50 | Add 20-25% of target allocation (Tranche 3) |
| $260 near 200 SMA ($246) with macro pivot | Add 15-20% of target allocation (Tranche 4) |
| Price above $315 without fresh catalyst | Begin trimming position (Trim 1) |
| Price at $325+ approaching 52-week high $334 | Full trim (Trim 2) |
| Scale-in zone ($260-275) not filled within 5 sessions before Q3 earnings | Deploy remaining 60-65% of capital within 5% of post-earnings price if Q3 confirms trajectory (revenue >$5.5B + FCF ≥$1.8B + GM ≥60% + book-to-bill >1.0) |
TXN is a compounder-in-recovery with a 62% earnings recovery already underway, trading at a reasonable forward P/E of 26.4x with elite ROE of 35.2%, operating margin of 42.6%, and FCF inflection that makes the bear's HOLD recommendation too cautious for this earnings trajectory.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 275.45 | bullish |
| close_50_sma | 270.19 | bullish |
| close_200_sma | 246.58 | bullish |
| macd | 3.32 | bullish |
| macds | 0.93 | bullish |
| macdh | 2.39 | bullish |
| rsi | 61.93 | neutral |
| boll | 267.88 | neutral |
| boll_ub | 285.42 | neutral |
| boll_lb | 250.34 | neutral |
| atr | 7.56 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $275 with macro stabilization or volume >6M
Then: Deploy 20-25% of target allocation
↩ rebuts: “Near 52-week high, limited upside”
EV: +19% · concedes: The bear's forward P/E concern is the strongest-sounding argument, though I argue they use the wrong lens (TTM vs forward); Beta of 1.31 does mean high volatility (though currently working for longs); China and trade risk is real but is sector-wide, not TXN-specific; Technical 'wait for pullback' to 270-275 zone is valid tactical risk management — the pullback will be the best buying opportunity of the quarter; Macro headwinds from rates are real concerns, though TXN's specific exposure is end-market sensitive rather than rate-sensitive
TXN at $281 is the wrong price for a great company — paying peak-cycle forward P/E of 26.4x (upper end of the 18-24x historical range) at 97% cycle recovery with an 11% rally already in the price, into a hawkish Fed regime with no fresh catalysts until late-October earnings.
· concedes: Q2 2026 was strong: revenue +22.8% YoY, net income $1.98B, EPS $2.14; TXN is a great company with best-in-class margins, fortress balance sheet, elite ROE, structural cost leadership from 300mm fabs; At $230-$250, would be a screaming buyer; Industrial/auto end markets are 'mixed-to-positive' (not actively deteriorating)
→ vs conservative: The 270-275 pullback target is a 'wait for cheaper' mentality that gets investors left behind; stock ripped 11% in 22 days on accelerating momentum and may never pull back, or if it does, it will signal fundamental breakdown
→ vs conservative: TTM P/E of 42.75x is anchoring on 2024 cyclical trough; forward P/E of 26.4x with 61.7% growth is the correct denominator; Q3 earnings will collapse TTM into mid-20s
→ vs neutral: Macro concerns (10-year yields, 97% Fed cut probability) already digested as TXN rallied 11% despite this backdrop; Q2 revenue acceleration is fundamental, not multiple-expansion story
| vwma | 269.18 | neutral |
Support: 270.19 · 267.88 · 250.34 · 246.58 | Resistance: 275.45 · 285.42
TXN exhibits a confirmed bullish trend structure with stacked moving averages, positive and expanding MACD histogram (+2.39), and RSI in healthy uptrend territory (61.93). Price (281.31) has rallied ~11% in 22 sessions from the 253.34 swing low, currently riding near the upper Bollinger band at 285.42. Primary risk is the extended gap between price and VWMA (269.18), suggesting a pullback to the 270–275 zone (50 SMA/10 EMA confluence) would offer better risk/reward for new entries. ATR of 7.56 implies reasonable stop placement ~11–15 points below entry. A decisive close below 267.88 (BOLL middle) would signal trend weakness.
Market Cap
$256.9B
Beta
1.314
Current Price (Implied)
~$281
52-Week High
$334.03
52-Week Low
$152.73
50-Day Avg
$270.62
200-Day Avg
$247.72
P/E (TTM)
42.75x
Forward P/E
26.43x
PEG Ratio
1.0
Price/Book
14.26x
Dividend Yield
2.17%
EPS (TTM)
$6.58
Forward EPS
$10.64
Revenue (TTM)
$19.45B
Gross Profit (TTM)
$11.35B
EBITDA
$9.52B
Net Income
$6.02B
Operating Margin
42.6%
Profit Margin
31.1%
ROE
35.2%
ROA
13.1%
FCF (TTM)
$3.55B
Q2 2026 Revenue
$5,463M
Q2 2026 Net Income
$1,980M
Q2 2026 Diluted EPS
$2.14
Q2 2026 FCF
$2.19B
Q1 2026 Revenue
$4,825M
Q4 2025 Revenue
$4,423M
Q3 2025 Revenue
$4,742M
Q2 2025 Revenue
$4,448M
2025 Revenue
$17.68B
2024 Revenue
$15.64B
2023 Revenue
$17.52B
2022 Revenue
$20.03B
2021 Revenue
$20.03B
2025 CapEx
$4.55B
2023 CapEx
$5.07B
2025 FCF
$2.60B
2024 FCF
$1.50B
2023 FCF
$1.35B
2022 FCF
$5.92B
2021 FCF
$5.92B
2025 Net Income
$5.00B
2024 Net Income
$4.80B
2023 Net Income
$6.51B
2022 Net Income
$8.75B
2021 Net Income
$8.75B
2025 Diluted EPS
$5.45
2024 Diluted EPS
$5.20
2023 Diluted EPS
$7.07
2022 Diluted EPS
$9.41
2021 Diluted EPS
$9.41
2025 Dividends Paid
$5.00B
2024 Dividends Paid
$4.80B
2023 Dividends Paid
$4.56B
2022 Dividends Paid
$4.30B
2021 Dividends Paid
$4.30B
2025 Operating CF
$7.15B
2024 Operating CF
$6.32B
Q2 2026 Operating CF
$2.70B
Q2 2026 CapEx
$0.51B
Q2 2026 Buybacks
$0.03B
Q2 2026 Total Assets
$35.88B
Q2 2026 Cash & ST Investments
$7.00B
Q2 2026 Total Debt
$14.05B
Q2 2026 Net Debt
$10.39B
Q2 2026 Stockholders' Equity
$18.01B
Q2 2026 Long-Term Debt
$12.90B
Q2 2026 Inventory
$4.61B
Q2 2026 Receivables
$2.52B
Current Ratio
4.86x
D/E Ratio
78.0%
Annual D&A
$1.92B
Strengths
Concerns
Texas Instruments is a mega-cap semiconductor company (~$256.9B market cap) with a fortress balance sheet (4.86x current ratio) and best-in-class profitability metrics (42.6% operating margin, 35.2% ROE). The company is in a clear cyclical recovery phase with Q2 2026 revenue accelerating to $5.46B (+22.8% YoY) and free cash flow inflecting sharply to $2.19B in Q2 alone, as the major capex cycle ($15B+ cumulative 2022-2025) normalizes. However, with the stock near 52-week highs and a TTM P/E of 42.8x (though forward P/E is more reasonable at 26.4x), much of the recovery narrative appears priced in, supporting a HOLD rating with tactical buy-on-pullback strategies (target $247-$270 zones) preferred over chasing at current levels.
Macro: Hawkish-leaning and rate-sensitive: 10-year Treasury yield touched highest level since 2002; Fed officials warning inflation remains too high; Polymarket pricing 97% probability of zero Fed rate cuts in 2026. Recession risk is benign (8% US recession by year-end 2026, down 2pp week-over-week). Chip/tech leading market rebound despite rate pressure; AI-related tech (IBM +5%, Accenture +20-23%, Infosys +8%, Synopsys, Micron, Fair Isaac) rewarding strong AI demand and resilient enterprise IT spending into 2027. Term premium/fiscal/inflation-driven long-end repricing rather than growth-scare dynamic.